Edgewise Therapeutics, Inc. (EWTX) · Aug 6, 2026 · Company update

Quarterly loss misses estimates as Servier deal funds cardiovascular pivot

Quarterly loss misses estimates as Servier deal funds cardiovascular pivot

The quarter missed the only meaningful published financial benchmark. EPS came in at a $0.53 loss versus a published consensus of roughly a $0.47 loss, a $0.06 miss; there is no revenue comparison because Edgewise remains pre-commercial.

MetricQ2 2026Comparison / expectation
Net loss$57.3 million$36.1 million in Q2 2025 (Income Statement)
Loss per share$0.53$0.34 loss in Q2 2025; approximately $0.47 expected
R&D expense$47.5 million$33.6 million in Q2 2025 (Income Statement)
G&A expense$14.4 million$9.1 million in Q2 2025 (Income Statement)
Cash, equivalents and marketable securities$460.7 million$530.1 million at December 31, 2025 (Balance Sheet)
Pro forma cash after upfront proceeds$2.01 billionIncludes $1.55 billion received from Servier; before taxes and transaction costs (Cash, cash equivalents and marketable securities)

The balance-sheet transformation is the bigger event, but it was largely known already. The previously announced Servier transaction closed in July, transferring sevasemten and the muscular dystrophy business for $1.55 billion upfront and up to $1.1 billion in milestones; the filing mainly confirms completion and shows the resulting pro forma cash position (Transaction highlights; Cash, cash equivalents and marketable securities).

The company now has unusually strong funding for a narrower, cardiovascular-focused pipeline. Management reiterated plans to start an EDG-7500 Phase 3 HCM trial in the fourth quarter of 2026 and an EDG-15400 HFpEF Phase 2 trial in the second half of 2026, while quarterly R&D rose 42% year over year to support those programs (CIRRUS-HCM Phase 2; EDG-15400 and heart failure; R&D expenses). That improves financial flexibility, but the filing adds no new efficacy data beyond the previously announced positive top-line CIRRUS-HCM results.

Net read: a financial miss offset by a strategically important but already anticipated funding event. The EPS shortfall and rising operating costs are mildly unfavorable, while the $2.01 billion pro forma cash balance materially reduces near-term financing risk; with no new clinical upgrade or surprise milestone, the overall message is mixed rather than clearly positive.

Original filing on SEC EDGAR

More Edgewise Therapeutics, Inc. news

Quarterly loss misses estimates as Servier deal funds cardiovascular pivot | EWTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.